Transcriptional Profiling of Peripheral Blood in Pancreatic Adenocarcinoma Patients Identifies Diagnostic Biomarkers

Caba, Octavio; Prados, José; Ortíz, Raúl; Jiménez-Luna, Cristina; Melguizo, Consolación; Álvarez, Pablo; Delgado, Juan Ramón; Irigoyen, A.; Rojas, Ignacio; Pérez-Florido, Javier; Torres, Carolina; Perales, Sonia; Linares, Ana María; Aránega, Antonia

doi:10.1007/s10620-014-3291-3

Cited by 28 publications

(27 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It codes for a protein with no known function. The ANKRD22 transcripts are increased in the blood of patients with pancreatic cancer 41 or during ovulation. 42 Two transcripts, GBP5 and AIM-2, which were upregulated in all 3 of the tissues we studied, play a role in regulating inflammasomes, which are intracellular proteins that control the activation of IL-1 β.…”

Section: Discussionmentioning

confidence: 99%

Parallel Gene Expression Changes in Sarcoidosis Involving the Lacrimal Gland, Orbital Tissue, or Blood

et al. 2015

View full text Add to dashboard Cite

IMPORTANCE Sarcoidosis is a major cause of ocular or periocular inflammation. The pathogenesis of sarcoidosis is incompletely understood and diagnosis often requires a biopsy.OBJECTIVE To determine how gene expression in either orbital adipose tissue or the lacrimal gland affected by sarcoidosis compares with gene expression in other causes of orbital disease and how gene expression in tissue affected by sarcoidosis compares with gene expression in peripheral blood samples obtained from patients with sarcoidosis. DESIGN, SETTING, AND PARTICIPANTSIn a multicenter, international, observational study, gene expression profiling of formalin-fixed biopsy specimens, using GeneChipp U133 Plus 2 microarrays (Affymetrix), was conducted between October 2012 and January 2014 on tissues biopsied from January 2000 through June 2013. Participants included 12 patients with orbital sarcoidosis (7 in adipose tissue; 5 affecting the lacrimal gland) as well as comparable tissue from 6 healthy individuals serving as controls or patients with thyroid eye disease, nonspecific orbital inflammation, or granulomatosis with polyangiitis. In addition, results were compared with gene expression in peripheral blood samples obtained from 12 historical individuals with sarcoidosis. MAIN OUTCOMES AND MEASURESSignificantly differentially expressed transcripts defined as a minimum of a 1.5-fold increase or a comparable decrease and a false discovery rate of P < .05.RESULTS Signals from 2449 probe sets (transcripts from approximately 1522 genes) were significantly increased in the orbital adipose tissue from patients with sarcoidosis. Signals from 4050 probe sets (approximately 2619 genes) were significantly decreased. Signals from 3069 probe sets (approximately 2001 genes) were significantly higher and 3320 (approximately 2283 genes) were significantly lower in the lacrimal gland for patients with sarcoidosis. Ninety-two probe sets (approximately 69 genes) had significantly elevated signals and 67 probe sets (approximately 56 genes) had significantly lower signals in both orbital tissues and in peripheral blood from patients with sarcoidosis. The transcription factors, interferon-response factor 1, interferon-response factor 2, and nuclear factor κB, were strongly implicated in the expression of messenger RNA upregulated in common in the 3 tissues.CONCLUSIONS AND RELEVANCE Gene expression in sarcoidosis involving the orbit or lacrimal gland can be distinguished from gene expression patterns in control tissue and overlaps with many transcripts upregulated or downregulated in the peripheral blood of patients with sarcoidosis. These observations suggest that common pathogenic mechanisms contribute to sarcoidosis in different sites. The observations support the hypothesis that a pattern of gene expression profiles could provide diagnostic information in patients with sarcoidosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Parallel Gene Expression Changes in Sarcoidosis Involving the Lacrimal Gland, Orbital Tissue, or Blood

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The co-expression of CXCR6 and CXCL16 , a chemokine ligand and receptor, has been associated with inflammatory response and cell migration [57, 58]. In addition, high levels of HCST [59, 60], C3AR1 [61], GBP4 [62], LY96 [63], ANKRD22 [64], FPR3 [65] and FCGR2A [66], have also been related to immune activation and/or inflammatory response in tumours; however, their role in basal-like breast malignancies are yet to be uncovered. In our study, the increased expression levels of these probes, among others genes in the signature, has brought new insights on the basal-like tumour origin and progression, and Basal I and Basal II differentiation.…”

Section: Discussionmentioning

confidence: 99%

Basal-like breast cancer: molecular profiles, clinical features and survival outcomes

et al. 2017

View full text Add to dashboard Cite

BackgroundBasal-like constitutes an important molecular subtype of breast cancer characterised by an aggressive behaviour and a limited therapy response. The outcome of patients within this subtype is, however, divergent. Some individuals show an increased risk of dying in the first five years, and others a long-term survival of over ten years after the diagnosis. In this study, we aim at identifying markers associated with basal-like patients’ survival and characterising subgroups with distinct disease outcome.MethodsWe explored the genomic and transcriptomic profiles of 351 basal-like samples from the METABRIC and ROCK data sets. Two selection methods, labelled Differential and Survival filters, were employed to determine genes/probes that are differentially expressed in tumour and control samples, and are associated with overall survival. These probes were further used to define molecular subgroups, which vary at the microRNA level and in DNA copy number.ResultsWe identified the expression signature of 80 probes that distinguishes between two basal-like subgroups with distinct clinical features and survival outcomes. Genes included in this list have been mainly linked to cancer immune response, epithelial-mesenchymal transition and cell cycle. In particular, high levels of CXCR6, HCST, C3AR1 and FPR3 were found in Basal I; whereas HJURP, RRP12 and DNMT3B appeared over-expressed in Basal II. These genes exhibited the highest betweenness centrality and node degree values and play a key role in the basal-like breast cancer differentiation. Further molecular analysis revealed 17 miRNAs correlated to the subgroups, including hsa-miR-342-5p, -150, -155, -200c and -17. Additionally, increased percentages of gains/amplifications were detected on chromosomes 1q, 3q, 8q, 10p and 17q, and losses/deletions on 4q, 5q, 8p and X, associated with reduced survival.ConclusionsThe proposed signature supports the existence of at least two subgroups of basal-like breast cancers with distinct disease outcome. The identification of patients at a low risk may impact the clinical decisions-making by reducing the prescription of high-dose chemotherapy and, consequently, avoiding adverse effects. The recognition of other aggressive features within this subtype may be also critical for improving individual care and for delineating more effective therapies for patients at high risk.Electronic supplementary materialThe online version of this article (doi:10.1186/s12920-017-0250-9) contains supplementary material, which is available to authorized users.

show abstract

“…It has been reported that the expression of ANKRD22 in peripheral blood samples can be used for the diagnosis of pancreatic ductal adenocarcinoma 20 . The present study shows, for the first time, that there is an association between the up-regulation of ANKRD22 and tumor progression in NSCLC.…”

Section: Discussionmentioning

confidence: 99%

ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1

Yin

Dai

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Lung cancer is the leading cause of death among all malignancies due to rapid tumor progression and relapse; however, the underlying molecular mechanisms of tumor progression are unclear. In the present study, we identified ANKRD22 as a novel tumor-associated gene in non-small cell lung cancer (NSCLC). According to the clinical correlation analysis, ANKRD22 was highly expressed in primary cancerous tissue compared with adjacent cancerous tissue, and high expression levels of ANKRD22 were significantly correlated with relapse and short overall survival time. Knockdown and overexpression analysis revealed that ANKRD22 promoted tumor progression by increasing cell proliferation. In xenograft assays, knockdown of ANKRD22 or in vivo treatment with ANKRD22 siRNA inhibited tumor growth. Furthermore, ANKRD22 was shown to participate in the transcriptional regulation of E2F1, and ANKRD22 promoted cell proliferation by up-regulating the expression of E2F1 which enhanced cell cycle progression. Therefore, our studies indicated that ANKRD22 up-regulated the transcription of E2F1 and promoted the progression of NSCLC by enhancing cell proliferation. These findings suggest that ANKRD22 could potentially act as a novel therapeutic target for NSCLC.

show abstract

Transcriptional Profiling of Peripheral Blood in Pancreatic Adenocarcinoma Patients Identifies Diagnostic Biomarkers

Abstract: Peripheral blood gene expression profiling is an useful tool for the diagnosis of PDAC. We present a validated four-gene predictor set (ANKRD22, CLEC4D, VNN1, and IRAK3) that may be useful in PDAC diagnosis.

Cited by 28 publications

References 35 publications

Parallel Gene Expression Changes in Sarcoidosis Involving the Lacrimal Gland, Orbital Tissue, or Blood

Parallel Gene Expression Changes in Sarcoidosis Involving the Lacrimal Gland, Orbital Tissue, or Blood

Basal-like breast cancer: molecular profiles, clinical features and survival outcomes

ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1

Contact Info

Product

Resources

About